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Abstract: Cannabis sativa (Cannabis) is one of the world’s most well-known, yet maligned plant
species. However, significant recent research is starting to unveil the potential of Cannabis to pro-
duce secondary compounds that may offer a suite of medical benefits, elevating this unique plant
species from its illicit narcotic status into a genuine biopharmaceutical. This review summarises the
lengthy history of Cannabis and details the molecular pathways that underpin the production of key
secondary metabolites that may confer medical efficacy. We also provide an up-to-date summary
of the molecular targets and potential of the relatively unknown minor compounds offered by the
Cannabis plant. Furthermore, we detail the recent advances in plant science, as well as synthetic
biology, and the pharmacology surrounding Cannabis. Given the relative infancy of Cannabis research,
we go on to highlight the parallels to previous research conducted in another medically relevant and
versatile plant, Papaver somniferum (opium poppy), as an indicator of the possible future direction
of Cannabis plant biology. Overall, this review highlights the future directions of cannabis research
outside of the medical biology aspects of its well-characterised constituents and explores additional
avenues for the potential improvement of the medical potential of the Cannabis plant.
Keywords: Cannabis sativa (Cannabis); cannabinoids; tetrahydrocannabinol (THC); cannabidiol (CBD);
cannabinoid receptors (CB1 and CB2); Papaver somniferum (opium poppy); secondary metabolites
1. Introduction
Cannabis sativa (Cannabis) is arguably one of the world’s most versatile crops. While the
genetic origin and evolution of Cannabis is a long-standing and heavily debated topic [1–4],
in broad terms, today, Cannabis can be separated into two distinct categories, specifically
‘hemp’ and ‘marijuana’. Much like other agricultural crop commodities, Cannabis has been
domesticated and bred for thousands of years to produce phenotypic and/or chemotypic
traits of value to humans [2–5]. The chemotypic distinction between hemp and marijuana
predominantly stems from the abundance of the principal psychoactive cannabinoid, ∆9-
tetrahydrocannabinol (THC), present in the plant as the acidic form, ∆9-tetrahydrocannabinolic
acid (THCA) [6]. To be considered hemp, Cannabis must possess a low percentage of THC
relative to the total dry weight of flowers, with this low THC percentage varying from coun-
try to country. In order to be legally cultivated as hemp, the cultivated plants must possess
less than 0.3% THC (w/w) in Canada [4,7] and China [8], whereas since 2001, the European
Union determined that the THC content (w/w) of hemp must be below 0.2% [6].
Hemp has traditionally been bred as a source for textile products due to the strong,
elongated bast fibres present in the phloem of the stem. More recently, the elevated cel-
lulosic content of hemp cell walls has garnered interest in the plant as a source for the
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development of sustainable biofuel production [6]. Hempseed, and hempseed oil, have his-
torically been utilised as a food source, with more contemporary research revealing their
unique dietary value. In particular, the essential polyunsaturated fatty acids (PUFAs),
linoleic acid (LA) and linolenic acid (LNA), comprise 50–70% and 15–25% of the total fatty
acid content of hempseed, respectively; a 3:1 ratio promoted as nutritionally optimal [9–13].
PUFAs found in hempseed oil are incorporated into phospholipid bilayers and are integral
to membrane fluidity and the maintenance of its permeability [14]. Moreover, the two pro-
teins, edestin and albumin found in hempseed, contain rich amino acid profiles comparable
to that of high-quality soybean and egg white [15]. Given the functions and importance
of both fatty and amino acids, hempseed and hempseed oil may have some potential,
albeit minor, for reducing the incidence of certain diseases, while in parallel conferring a
range of health benefits [15–17]. Alternatively, marijuana has traditionally been bred for
its recreational intoxication properties derived from the THCA-containing resin produced
on the protruding secretory hair-like structures known as trichomes which are predom-
inantly located on female reproductive parts of the Cannabis plant [18,19]. The sticky
resin produced from these specialised epidermal glands is a rich mix of cannabinoid
and non-cannabinoid constituents, numbering at least 104 and 441, respectively [20,21].
Most recently, two novel cannabinoids, namely ∆9-tetrahydrocannabiphorol (∆9-THCP)
and cannabidiphorol (CBDP), near identical in structure to THC and cannabidiol (CBD),
respectively, were identified [22]. Notably, ∆9-THCP was demonstrated to possess higher
cannabimimetic activity than THC, and its recent discovery is therefore postulated as a
potential candidate cannabinoid responsible for variation in pharmacological properties ob-
served in uncharacterised Cannabis varieties. This also identifies the likelihood of secondary
metabolites present in Cannabis resin that remain to be discovered.
In addition to possessing a range of phenotypic and chemotypic traits of interest
to the textile, medicinal, food and energy industries as an agricultural crop, Cannabis is
extremely versatile and hardy, hence the application of the colloquial term for this species,
‘weed’. The phenotypic flexibility of Cannabis provides it with the capacity to adapt and
survive a range of abiotic and biotic insults, such as drought [23], heavy metal stress [24],
high temperature [25], poor soil nutrient content [3], high plant density [26], and stem
damage from the larva of Ostrinia nubilalis, the European corn borer [27]. Tolerance to
a range of abiotic stress conditions is exemplified by the tap root of Cannabis which is
able to adapt to highly variable edaphic conditions, either penetrating deep (greater than
2 metres) into dry soil, or developing an extensive lateral root network in response to its
growth in soil that has a high moisture content [26]. Further, the widespread legalisation
of medicinal application and recreational use of Cannabis is driving the growth of diverse
research programs encompassing the broad scope, from plant breeding to clinical trials.
In the United States of America (USA), for example, to date, 33 states have approved the
medicinal use of Cannabis, while 14 states and territories have legalised the recreational
use of marijuana by adults. At the federal level in the USA, however, Cannabis remains
a ‘Schedule I Substance’. In direct contrast to the heavy legislation of Cannabis in the USA,
its direct neighbour, Canada, legalised the use of Cannabis across the country in 2018 under
the ‘Cannabis Act’ [28]. As the legislative approval of Cannabis use increases worldwide,
there will be an increasing need for interdisciplinary research to characterise secondary
metabolites of interest and to increase the production of Cannabis to meet the demand for
medicinal and recreational products.
Currently, there exists an extant literature on the medical potential for the best charac-
terised cannabinoids, THC and CBD [29–34]. Significantly less attention in medical research
has been paid to the potential for the minor phytocannabinoids to treat illnesses, and there
is still the need for methods to produce these cannabinoids cost-effectively for commercial
production. In particular, the medical Cannabis industry faces significant challenges in
multiple aspects of product development. For instance, THC is associated with multiple
side effects, and furthermore, pharmaceutical-standard THC and CBD are expensive to
produce. Due to these hurdles, many companies around the world which have attempted
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to capitalise on the increasing legality of Cannabis have been unsuccessful [35]. Therefore,
here we review the current literature describing emerging research concerning the medical
potential of the minor cannabinoids, as well as to outline the agricultural and production
considerations that will be necessary to meet the needs of the growing medical market.
Readers interested primarily in the effects of CBD and THC should consult any of the
substantial reviews on these topics that are published elsewhere and referred to here in
Section 2.2. It should also be noted that there are some recent review articles on the molecu-
lar targets of the minor cannabinoids [36,37], but to the best of our knowledge, no published
review of the current literature has combined this research with the potential for improv-
ing Cannabis yield and extraction efficacy to make these possibilities economically and
logistically pragmatic. This review therefore presents a novel, interdisciplinary perspective
on the practical possibilities for improving the Cannabis species for its utilisation in the
cannabinoid industry in the near future.
2. The Endocannabinoid System and Its Associated Molecular Targets
2.1. An Overview of the Endocannabinoid System
The discovery of the endogenous cannabinoid system followed the initial isolation [38]
and synthesis [39] of the primary psychoactive compound in Cannabis, THC. Following on
from this in the late 1980s, and into the early 1990s, two cannabinoid receptors, CB1 and
CB2, were identified [40,41]. Surprisingly, it was discovered that CB1 was highly abundant
in the central nervous system (CNS), and in the CNS, CB1 is one of the most profuse G
protein-coupled receptors [42]. The identification of these two CB receptors subsequently
led to the discovery of an endogenous receptor ligand termed arachidonylethanolamide
(anandamide), a receptor ligand accurately predicted to exist based on the presence of the
CB receptors themselves [43]. A second receptor ligand, 2-arachidonoylglycerol (2-AG)
was later identified [44,45]. Anandamide and 2-AG are both synthesised from arachi-
donic acid. Synthesis of anandamide is complex, and therefore remains to be elucidated,
though it is thought to occur largely via the cleavage of arachidonic acid by a phospho-
lipase D from its membrane precursor, N-arachidonoyl phosphatidylethanolamine [46].
The synthesis of 2-AG occurs following the conversion of diacylglycerol by the metabolic
enzyme, diacylglycerol lipase (DAGL). Hydrolysis of anandamide occurs via the enzyme
activity of fatty acid amide hydrolase (FAAH), whereas 2-AG is hydrolysed by both FAAH
and monoacylglycerol lipase (MAGL) [47]. Inhibition of these enzymes increases anan-
damide and 2-AG concentrations and has therapeutic potential [48–50]. Similarly, it is
possible that modulation of precursory compounds of anandamide and 2-AG may have
therapeutic potential [51].
Previous investigations into CB receptor distribution within the fetal, neonatal and
adult human brain revealed that the CB receptors were primarily localised to areas re-
sponsible for; (1) higher cognitive function; (2) movement, and; (3) control of sensory and
motor functions of the autonomic nervous system [52]. Protein crystallisation has revealed
the structure of CB1 [53] and CB2 [54] to assist in the characterisation of the molecular
binding of ligands, such as THC, and potentially other key cannabinoids, both naturally
or synthetically produced. Using radiolabelled synthetic cannabinoids, it was shown that
the highest density of cannabinoid binding, and thus CB receptor localisation, appeared in
the basal ganglia, hippocampus and cerebellum [42]. Cannabinoids were shown to func-
tion on hippocampal presynaptic receptors, via regulating the release of γ-aminobutyric
acid (GABA) to modulate higher cognitive functions, while also increasing the activity of
p38 mitogen-activated protein kinases [55,56]. Similarly, GABA modulation in the basal
ganglia, specifically the presynaptic striatal projection neuron axons and their termini,
was found to be stimulated to differing degrees by either endocannabinoids or synthetic
cannabinoids [57,58]. The binding of the CB1 receptor by both endogenous and exogenous
cannabinoids also modulates excitatory synaptic transmission in Purkinje cells located in
the cerebellum [59–62]. Crucially, endocannabinoid signalling was recognised as the medi-
atory secondary messenger responsible for long-term potentiation, and depression [49,63],
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which are both fundamental to the control of synaptic transmission. CB1 receptors and
endocannabinoid signalling also interacts with other systems in the brain, such as the
dopaminergic [64], and glucocorticoid [65] pathways, to modulate stress response and
associative learning processes.
While early understanding of receptor distribution suggested exclusive ‘central’ aggre-
gation in specific regions of the brain, it is now understood that there is a more extensive
presence of CB1 type receptors in peripheral tissues. Two CB1 receptor isoforms have since
been identified, both of which display distinct expression patterns in pancreatic β-cells and
liver hepatocytes [66]. Antagonism of peripheral CB receptors located in skeletal muscles
was shown to trigger glucose uptake, while simultaneously initiating lipid mobilisation in
white adipose tissue [67]. Though the protein expression pattern of CB1 does show some
overlap with CB2 in peripheral tissues, and conversely some CB2 receptors are cerebrally
positioned [68–72], peripheral receptors are predominantly CB2 type receptors. Analy-
sis of CB2 transcript levels has previously revealed its expression in the tonsils, spleen,
and peripheral blood mononuclear cells, where further cell isolation showed detectable CB2
transcript levels in polymorphonuclear neutrophils (PMN), T4 cells, T8 cells, natural killer
(NK) cells, macrophages, and B cells. However, at the protein level, the CB2 receptor
appears to be restricted to B cells [73]. Similarly, CB2 receptor binding has been observed
in other immune system regions, namely the lymph node cortex, as well as in the Peyer’s
patches, which are areas of B lymphocyte aggregation [74]. The expression and/or local-
isation of functional CB2 protein has also been reported for mast cells, modulating their
initial activation, or downregulating their activity post their initial activation, an activity
change which can in turn provoke an anti-inflammatory response [75]. Anandamide and
2-AG, as well as their metabolic enzymes, are detectable in blood [76,77], hair [78–80],
saliva [81–83], breast milk [84,85], and reproductive fluids [84,86]. Compounded with
the peripheral anti-inflammatory response, CB2 receptor agonists can mediate peripheral
antinociception without the psychotropic CNS effects associated with phytocannabinoid
CB1 receptor binding [87,88]. This characteristic of exerting medically beneficial effects,
while simultaneously avoiding any psychotropic responses, is likely to form a key focus of
future cannabinoid research.
2.2. The Expanded Cannabinoid System and Its Less Characterised Receptors
It has been clearly demonstrated that the collective effects of cannabinoid administra-
tion cannot be explained solely by the presence of CB receptors. Conversely, it has been
increasingly recognised that cannabinoids have the potential to affect other molecular tar-
gets and receptor types, particularly given their role as presynaptic secondary messengers
on various neuron species [89,90] (Table 1). One such receptor is the G protein-coupled
receptor (GPCR), GPR55, with the GPR55 transcript identified in the adrenals, jejunum,
and ileum in mammalian systems [91]. Studies on canine, rat and mouse gastrointestinal
systems collectively suggest that GPR55 may be involved in smooth muscle contractions
and colonic motility, especially when activated by CBD, pointing to a potential target
for treatment of some gastrointestinal disorders [92–95]. Human embryonic kidney 293
(HEK293) cells expressing the GPR55 protein have been assessed for their response when
treated with the lysolipid, L-α-lysophosphatidylinositol (LPI), as well as following their
treatment with endogenous, synthetic or phytocannabinoids. LPI was found to induce phos-
phorylation of the protein, extracellular signal-related kinase (ERK) in GPR55-expressing
cells, while also initiating a transient Ca2+ signal involved in downstream messaging and
intracellular processing [96]. The degree of elevation in the concentration of Ca2+ increases
in HEK293 cells when mediated by GPR55-phospholipase C coupling varied depending on
whether THC, anandamide, methanandamide or the CB2 agonist, JWH015 was adminis-
tered [97]. However, there was no Ca2+ response initiated by CBD, the CBD regioisomer
abnormal CBD, the endogenous cannabinoids, 2-arachidonoylglycerol and O-arachidonoyl
ethanolamine, or the synthetic cannabinoids, WIN55,212-2 and CP55,940 [97]. Beyond Ca2+
transients, cannabinoid ligand interaction with the GPR55 receptor promotes ERK phos-
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phorylation, as well as the varied activation of cyclic adenosine monophosphate (cAMP)
response element binding protein (CREB), nuclear factor-κB (NF-κB) and nuclear factor
of activated T-cell (NFAT) transcription factors, the latter two of which are involved in
inflammation of endothelial cells and irritable bowel syndrome (IBS) [98–101]. The GPR55
transcript can also be found in the basal ganglia, hippocampus, forebrain, cerebellum,
cortex and large dorsal root ganglion (DRG) [97,102–104]. The expression of GPR55 in these
tissues significantly broadens the potential for its therapeutic application. For instance,
activation of the GPR55 receptor by THC enhances neuronal excitability and reduces the
M-type potassium current, which when combined with the expression pattern of GPR55
in the large DRG, indicates a nociceptive role [97]. Inflammatory pain was modulated by
abnormal CBD through GPR55 antagonism in acute arthritis models in rats [105]. Evi-
dence of pro-nociception was observed in rats when the abundance of GPR55-dependent
Ca2+ increased in periaqueductal grey neurons and which preceded a pain threshold re-
duction [106]. However, another study [107] reported that GPR55 knockout mice show no
difference to wild-type mice in neuropathic pain models.
Another seven-transmembrane G protein-coupled receptor, termed GPR18, was first
identified in canine gastric mucosa and a human colonic cancer cell line, with a high abun-
dance of the GPR18 transcript detected in human testis and spleen tissue [108]. The candi-
date ligand was later suggested to be N-arachidonoyl glycine (NAGly), an anandamide
metabolite, which was first detected when GPR18-expressing cell lines, including the L929,
K562 and Chinese hamster ovary (CHO) cell lines produced, high levels of intracellular
Ca2+ and inhibited the production of cAMP following NAGly exposure [109]. In addition,
quantitative real-time PCR analysis revealed high levels of GPR18 expression in peripheral
lymphocytes, further supporting the suggestion of a role in immune system function [109].
The transient receptor potential vanilloid (TRPV) channels are a subfamily of trans-
membrane ligand-gated ion channels that mediate signal transduction processes initiated
by a broad range of noxious stimuli in animals, with the TRPVs, TRPV1 through to TRPV4,
activated to varying degrees via cannabinoid application. TRPV expression in several
human tissues and the documented role of TRPVs in human disease is a current av-
enue of interest. The capsaicin and temperature (~42 ◦C) responsive TRPV1, displays an
ambiguous expression profile. However, the weight of evidence suggests that its ex-
pression domain is rather broad in animal systems. Specifically, the TRPV1 protein was
observed to be localised to the dorsal root and trigeminal ganglions [110], thermoregula-
tory tissue smooth muscle cells [111], urothelial cells [112], corneal fibroblasts [113], and a
broad distribution profile in the brain, including the hippocampus, cortex and olfactory
bulb [114]. Sharing 50% sequence identity to TRPV1, TRPV2 has been demonstrated to
respond to high-intensity thermal stimuli (~52 ◦C). However, unlike TRPV1, TRPV2 is
insensitive to capsaicin [115]. Given its sensory involvement, TRPV2 localisation in the
ganglia is unsurprising. However, TRPV2 is also localised to the brain, lung, spleen, in-
testine, mast cells and lymphocytes [115–118], which, when considered together, infers
additional TRPV2 function beyond heat sensing, and by extension, activation by non-
thermal receptor modulators. The initiation of signal cascades via TRPV2 are potentially
involved in diseases and physiological responses including cancer [119], the innate and
adaptive immune responses [116,117,120,121], cardiomyopathy [122,123], muscular dystro-
phy [124,125], and insulin secretion response [126–128].
The cannabinoid-responsive TRPVs, TRPV3 and TRPV4, are also temperature sen-
sitive proteins. The responsive temperature range (27–40 ◦C) for these two receptors is
below that of TRPV1 and TRPV2, but they do closely overlap with one another [129–132].
Their thermosensory involvement localises these two TRPVs to keratinocytes, where they
sense warmth on the skin and transmit a signal to nearby neurons [133–138]. In the tongue
and nasal epithelium, TRPV3 is activated by the ‘pungent’ carvacrol as well as by thymol
and camphor [133,139], whereas the mevalonate (MVA) pathway product and cannabi-
noid/terpenoid precursor, isopentenyl diphosphate (IPP), has been shown to inhibit TRPV3
activity [140]. TRPV4, in association with aquaporin 5 (AQP5), is additionally involved
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in osmosensing and regulatory volume decrease in cells following swelling in hypotonic
environments [141–144]. Located in the brain [145,146], kidneys [147], CNS [148], and en-
docardium [149], TRPV4 activity is also modulated by phorbol esters and arachidonic acid
expanding its activation beyond physical stimuli [150,151].
In addition to the vanilloid subtype of the transient receptor potential channels are
the melastatin and ankyrin subtypes. Of the melastatin type, transient receptor potential
melastatin 8 (TRPM8) is a cold/menthol-responsive channel located in the DRG and
trigeminal ganglia [152,153]. Of the ankyrin subtype, transient receptor potential ankyrin 1
(TRPA1) acts similarly to TRPM8 in response to cold stimuli covering a similar temperature
range (~8–28 ◦C). However, it is suggested that TRPA1 contributes to sensation of lower
temperatures, and is also similarly localised in sensory neurons [154–157]. TRPA1 is
additionally activated by formalin and allyl isothiocyanates such as mustard oil [158,159],
and has further been implicated in eliciting inflammatory pain [160–163].
Multiple other targets show notable interactions with the endocannabinoid system;
however, a comprehensive description of all interactions is beyond the scope of this review.
Briefly, other notable molecular interactions include glycine receptors with anandamide,
and in addition, CBD and THC have also been shown to activate glycine receptors [164,165].
Further, THC appears to exhibit dose-dependent effects on glycine receptor activation [166].
The activation of peroxisome proliferator-activated receptors (PPAR), in particular the α and
γ subtypes, is responsible for many of the metabolic, analgesic, neuroprotective, and other
health-related benefits of cannabinoids [167]. Cannabinoids have also been shown to
interact with serotonergic sites, particularly with the 5-HT1A [168] and 5-HT2A [169,170]
receptors, and these interactions are strongly associated with disorders such as anxiety
and post-traumatic stress [171,172]. Consequently, the spectrum of potential therapeutic
applications is very broad for cannabinoids and would require a specifically dedicated and
lengthy review in its own right. Currently lacking are robust, double-blind in vivo and
clinical studies of the constituents of the broader cannabinoid profile that target specific
diseases, and/or can be used to treat the symptoms of these diseases, possibly via targeting
the interactions between cannabinoids and these other putative or lesser-known receptors.
Table 1. Receptor modulation by cannabinoids and studies outlining their potential involvement in disease treatment.
Receptor Cannabinoid Disease/Interaction Study Type Reference
CB1
Anandamide Appetite Murine models [173,174]
Met-F-AEA Thyroid cancer in vitro human [175]
THCB (PA) Pain Murine models [176]
THC (PA)
Epilepsy Murine models [177]
Sleep Various studies [178]
THCP (Ag)
Pain, anxiety, hypothermia,
catalepsy Murine models [22]
THCV (ˆ)
Pain, anxiety, hypothermia,
catalepsy Murine models [179,180]
Parkinson’s disease Murine models [181]
Obesity Murine models [182]
Epilepsy in vitro murine [183]
THC, WIN55,212-2,
CP55, 940 Emesis Animal models [184–188]
WIN55,212-2
Parkinson’s disease Murine model [189]
Prostate cancer in vitro human [190]
WIN55,212-2, JWH-133 Breast, lung cancer in vitro human [191,192]
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Table 1. Cont.
Receptor Cannabinoid Disease/Interaction Study Type Reference
CB2
CBC (Ag) Inflammation in vitro models [193]
CBG (PA) Inflammatory bowel disease Murine models [194]
HU-308, AM630 Parkinson’s disease Murine models [195,196]
THCP (Ag)
Pain, anxiety, hypothermia,
catalepsy Murine models [22]
THCV (ˆ) Inflammation Murine models [180]
CB2
THCV (ˆ)
Parkinson’s disease Murine models [181]
Pain, anxiety, hypothermia,
catalepsy Murine models [179]
WIN55,212-2 Prostate cancer in vitro human [190]
WIN55,212-2, JWH-133 Breast, lung cancer in vitro human [191,192]
GPR55 Abnormal CBD Parkinson’s disease Murine models [103]
GPR55
Abnormal CBD Pain/arthritis Murine models [105]
CBD (An) Gastrointestinal disorders Canine, murine models [93–96]
CBDV (An)
Rett syndrome Murine models [197]
LPI inhibitor in vitro [198]
THC, anandamide,
JWH015 Pain in vitro HEK239 [97]
TRPV1
CBDV (Ag) Anti-seizure in vitro HEK239 [199]
CBG (Ag), CBGV, CBD (Ag),
CBDV (Ag), THCV (Ag)
Receptor desensitisation in vitro HEK239 [200]
TRPV2
CBD (Ag), CBGV, CBG (Ag),
THCV (Ag), CBDV (Ag),
CBN (Ag)
Receptor desensitisation in vitro HEK239 [200]
TRPV3 CBGV, CBGA (Ag) Receptor desensitisation in vitro HEK239 [201]
TRPV4 CBGV, CBGA, CBN, CBG Receptor desensitisation in vitro HEK239 [201]
TRPM8
CBG (An), CBC (An), CBD
(An), CBDV (An), THC (An),
THCA (An)
Colorectal cancer in vitro model [200,202,203]
TRPA1
CBC (Ag), CBN (Ag), THC
(Ag), THCV (Ag), THCA
(Ag), CBDA, CBG (Ag)
Receptor desensitisation in vitro HEK239 [200,202]
CBDV (Ag)
Ulcerative colitis in vitro human [204]
Muscular dystrophy in vitro studies [205]
PA = Partial Agonist, Ag = Agonist, ˆ = Dose Dependent, An = Antagonist.
2.3. Examples of the Potential Medicinal Use of Cannabinoids
While research into the cannabinoids and their role in human disease is still in its
infancy, the field abounds in promising preliminary studies. Cannabinoids, both of the
endo- and phytocannabinoid categories, have been demonstrated to provide protection
against further neurodegeneration in lesioned neurons post-treatment with toxic doses of 6-
hydroxydopamine, as well as the neuron degeneration linked to Parkinson’s disease [189,206].
Moreover, symptoms of dyskinesia associated with Parkinson’s disease and other movement
disorders, originating from deficiencies in the cannabinoid receptor-rich basal ganglia in
marmosets, and reserpine-treated rats, have been reduced by CB1 receptor stimulation-
mediated suppression of involuntary motor behaviour [189,207–210]. Central nervous system
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activation of the CB2 receptor has exhibited promising results in combating the inflammation
and oxidative stress of Parkinson’s disease which is associated with dopaminergic neuron
loss in the substantia nigra pars compacta in nonhuman models [195,196].
Studies into the treatment of a variety of cancers through cannabinoid use have
also proved valuable. For example, CB1 and CB2 activation by either endogenous or
synthetic receptor ligands has inhibited prostate [190] and pancreatic [211] adenocarcinoma
growth, as well as breast [191] and thyroid [175] tumour growth. Modulation of non-
CB receptors by the minor cannabinoids is also under investigation for their role in the
initiation of oncogenic signalling cascades that may induce the arrest of the cell cycle,
or inhibit the growth of tumours [212]. Endocannabinoid-mediated breast cancer cell
proliferation has been inhibited by a reduction in prolactin action at the receptor level [213],
and CB1 and CB2 receptor activation has induced apoptosis of cancerous cells in the
breast [191] and colon [214]. In non-small-cell lung cancer cell lines, treatment with
agonists targeting CB1 and CB2, or specifically CB2, were demonstrated to induce apoptosis,
and to attenuate chemotaxis, metastatic growth and development, metastatic proliferation,
and angiogenesis [192]. Similarly, cannabinoid activity against vascularization was also
observed in human grade glioma cells in mice, with CB2 activation reducing tumour
angiogenesis by inhibiting vascular endothelial cell migration and the suppression of
pro-angiogenic factors in tumour cells [215].
First alluded to over 40 years ago, the use of Cannabis as a treatment for epilepsy has
garnered traction in recent years and several comprehensive reviews have recently described
the efficacy of cannabinoids in the treatment and/or management of epilepsy [216–218].
Further evidence of the involvement of the endocannabinoid systems in seizure mitigation is
suggested with inactivation of the endocannabinoid degrading, FAAH, with FAAH shown
to reduce both kainic acid associated seizure activity, and synaptic decline and damage to
cytoskeletal elements in the hippocampus of rat models [219,220]. A double-blind, placebo-
controlled study of 218 patients in which CBD was administered at a dose of 10 and 20 mg per
kg reduced the frequency of drop seizures in both children and adults with Lennox-Gastaut
syndrome, when compared to conventional epilepsy treatment [221]. A similar double-
blind, placebo-controlled study of 120 children with the epilepsy disorder, Dravet syndrome,
saw a significant reduction in the frequency of convulsive seizures when treated with CBD,
as compared with those administered the placebo [222]. In a retrospective, open-labelled
study, Press et al. [223] reported improvements in seizure control and frequency reduction in
paediatric patients using oral Cannabis extracts, as well as additional improvements in some
off-target metrics, including alertness and motor skill usage also observed. Use of a THC
extract has attenuated seizure duration and termination via the activation of CB1. However,
inhibition of CB1 receptor activity has also been demonstrated to increase the frequency and
duration of seizures in non-human models, findings which firmly identify a role for CB1
in seizure responses [177]. Indeed, transgenic CB1 overexpressing mice were reported to
have reduced kainic acid-induced seizure severity and mortality with reduced hippocampal
neuron damage [224]. While these examples suggest promise in the efficacy of cannabinoids,
or the modulation of cannabinoid receptor activity against epilepsy, there currently remains
deficiencies in access to data emerging from large, controlled clinical studies.
The treatment of Parkinson’s disease, cancer and epilepsy are persistently pursued
and remain ‘high-value’ targets for researchers. However, the importance of treating other
less deleterious ailments, or the treatment of the negative side effects that originate from the
aggressive treatment strategies of major diseases such as cancer, chemotherapy for example,
is not without utility. A suite of clinical trials have supported the ability of Cannabis-
derived metabolite constituents to (1) act as effective antiemetics [184–188], (2) ease the
spasticity symptoms associated with Motor Neuron Disease and Multiple Sclerosis [225],
(3) stimulate appetite [173,174,226–229], (4) help regulate sleep patterns [178,230–232],
(5) initiate analgesia [233–236], (6) act as an anxiolytic to alleviate the psychotic symptoms
of schizophrenia [237–241], (7) treat anxiety and post-traumatic stress disorders [31,171,242],
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(8) be utilised as palliative care agents [243,244], (9) aid in the acute inflammatory response
and its protracted recovery [245], and (10) mitigate the effects of opioid addiction [246,247].
A full review of the current understanding of cannabis in the medical sphere is beyond the
scope of this review and has been published elsewhere [90,248]. Despite much of the current
research remaining in the preliminary stages, requiring a greater amount of more stringent,
double-blind studies, the medicinal promise of Cannabis is readily evident. Meta-analyses
relating to the legitimacy of medical Cannabis, specifically the use of CBD and THC in control
randomised trials, have been conducted. Studies surrounding the use of CBD indicate that
the drug is well tolerated with minimal serious adverse side effects and drug–drug interac-
tions [249]. CBD is described as effective in the treatment of refractory seizures, but scientifically
stringent data are lacking to claim effectiveness for other indications, with concerns remaining
about the quality control in drug preparation and long-term safety [250]. It has been noted
that inconsistencies across current studies relating to dosage and administration methods limit
the conclusions that can be drawn to direct medical intervention using CBD [251]. Currently,
cannabinoid therapies for sleep quality and mental health-related disorders also suggest that
while preliminary evidence may indicate positive outcomes, the collation of eligible studies
provides insufficient evidence to suggest efficacy or promote usage until additional, and more
stringent studies have been conducted [252,253]. Although more stringent studies on the effec-
tiveness of cannabinoids to control pain and spasticity exist, additional comprehensive studies
demonstrating improvements in the treatment of chemotherapy associated nausea, sleep disor-
ders, weight gain, and Tourette’s syndrome, and which also note the risk of short-term adverse
events of cannabinoid treatment, are still required [32].
3. The Cannabinoid and Terpene Pathways of Cannabis
It is clear that modulation of the endocannabinoid system can be achieved outside of
THC, CBD, and their CB receptors. Despite this, the majority of research conducted to date has
sought to understand how these two cannabinoids interact with the various constituents of the
expanded endocannabinoid system. However, significant knowledge exists concerning what
further compounds can be extracted from Cannabis as well as an emerging understanding of
how such compounds can be efficiently extracted from the Cannabis plant. To date, the most
studied phytochemicals in Cannabis are the cannabinoids and terpenes. Together, these
two classes of phytochemical comprise approximately 41% of the total number of known
secondary metabolites identified in Cannabis [21,22]. Cannabinoid and terpenoid biosynthesis
occurs in hair-like capitate stalked glandular trichomes [254,255], which cover the female
floral organs, and exhibit a particularly high density on the bracts (a specialised leaf of the
floral organs; Figure 1).
In trichome development, a protodermal cell is enlarged vertically out from the
epidermis and subsequently undergoes anticlinal division, prior to a series of periclinal
division events to create a secretory and auxiliary tier of cells atop the epidermal basal
cells [256–259]. Additional division events develop the secretory tier of disc cells that
form a cavity on the external surface of the trichome from a portion of the outer wall.
This cavity then enlarges as the secretory vesicles that harbour a diverse payload of
secondary metabolites are extruded into the expanding waxy cavity. Post their cellular
release, the secreted vesicles disintegrate upon contact with the thickened outer cuticle
wall to release their contents [256–259].
The complete biosynthetic pathway of how the prenylated polyketides, particularly
minor cannabinoids, are derived from precursor molecules still requires further elucida-
tion, particularly in view of the recent discovery of the two novel cannabinoids, THCP and
CBDP [22]. Cannabigerolic acid (CBGA), the key intermediate substrate required for the
synthesis of the three primary cannabinoids—cannabichromenic acid (CBCA), THCA and
CBDA—arises from molecular products of the polyketide and methylerythritol 4-phosphate
(MEP) pathways. A schematic representation of the MEP pathway is provided in Figure 2A.
More specifically, the MEP pathway begins in the plastid via the condensation of the substrates,
pyruvate and triose phosphate, a reaction that is catalysed by 1-deoxy-D-xylulose-5-synthase
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(DXS), and which produces 1-deoxy-D-xylulose-5-phosphate (DXP) [260–262]. Via the action
of 1-deoxy-D-xylulose-5-reductase (DXR) in the presence of the co-factor NADPH, DXP is
next reduced to MEP [263] and subsequently, MEP is converted to CDP-ME by the action of
the enzyme, 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) synthase. The kinase,
DCP-ME kinase then phosphorylates CDP-ME to produce 4-diphospho-cytidyl-2-C-methyl-
D-erythritol-2-phosphate (CDP-ME2P) [264,265]. CDP-ME2P is subsequently converted to
2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-2,4cPP) via the activity of the enzyme,
ME-2,4cPP synthase, prior to another synthase, 4-hydroxy-3-methylbut-2-enyl diphosphate
synthase (HDS), converting ME-2,4cPP to 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate
(HDMPP). In the final step of the MEP pathway, HDMPP is used as a substrate by 4-hydroxy-
3-methylbut-2-enyl diphosphate reductase (HDR) to produce IPP and dimethylallyl diphos-
phate (DMAPP) [264–266].
The HDR enzyme is essential for the in planta production of IPP and DMAPP,
with over 98% of these two molecules produced by the MEP pathway. IPP and DMAPP
both form essential precursor substrates for the biosynthesis of cannabinoids and ter-
penoids [261]. In the cytosol, IPP is also produced by the MVA pathway (Figure 2B).
At the start of the MVA pathway, acetyl-CoA is converted to 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) by the enzyme, HMG-CoA synthase. Next, HMG-CoA is converted to
MVA in the highly rate-limiting step of the MVA pathway, a step that is regulated via the
activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) [267–269]. MVA is then
converted to MVA phosphate by MVA kinase (MVK), and subsequently, MVA phosphate
is converted to its diphosphate form via the activity of phospho-MVA kinase (PMK). MVA
diphosphate is subsequently converted to IPP via its decarboxylation by mevalonate 5-
diphosphate decarboxylase (MVD) [270–272]. Via the use of yellow fluorescent protein
(YFP) fusion constructs, the activity of PMK and MVD has been observed in the peroxisome
in Catharanthus roseus (Madagascar periwinkle) and Arabidopsis thaliana (Arabidopsis) to
strongly indicate peroxisomal localisation of these two enzymes in planta, and not in the
cytosol [270,271,273]. IPP isomerase catalyses the conversion between IPP and DMAPP,
a conversion reaction that provides the building blocks for terpene biosynthesis [274–276].
Geranyl diphosphate synthase (GPPS) catalyses the production of the ten-carbon (C10)
molecule, geranyl diphosphate (GPP), via the condensation of one molecule each of DMAPP
and IPP [277,278]. Similarly, formation of the C15 molecule, farnesyl diphosphate (FPP),
and the C20 molecule, geranylgeranyl-diphosphate (GGPP), is catalysed by their specific
synthases, farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase
(GGPPS), respectively, which condense either 2 or 3 molecules of IPP together with a single
molecule of DMAPP [279–281]. Together, GPP, FPP and GGPP form the precursors neces-
sary for monoterpene or CBGA biosynthesis (GPP precursor), or the numerous sesqui-, di-,
tri-, or tetra-terpene products (FPP or GGPP precursors) found in Cannabis [282,283].
Figure 1. A close up of the female floral architecture of mature Cannabis sativa plants. The cannabinoid-
containing glandular trichomes are visible in the magnified image, and are characterised by a globular
head which is connected to the plant via a stalk. Colouration of the heads ranges from translucent,
to a creamy white, to brown.
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Figure 2. An overview of the mevalonate and methylerythritol 4-phosphate pathways in Cannabis
sativa. The MEP (A) and MVA (B) pathways both produce terpenoid precursors, as well as the
substrate for cannabinoid production, GPP. (A) The MEP pathway begins in the plastid with the
condensation of pyruvate and glyceraldehyde 3-phosphate by DXS to produce DXP, prior to a series of
enzymatic reactions to produce HDMPP. HDR then converts HDMPP to IPP and DMAPP, serving as
the precursor to GPP, GGPP, and subsequently monoterpene and diterpene production. (B) The
cytosolic MVA pathway is initiated by the conversion of acetyl-CoA to HMG-CoA and then to MVA,
catalysed by the regulated, and rate-limiting enzyme, HMGR. MVA undergoes phosphorylation and
then is decarboxylated to produce IPP, which is then converted to FPP as the basis for sesquiterpene
and triterpene synthesis, or for GPP production for use in the cannabinoid biosynthesis pathway.
The polyketide pathway is initiated when acetyl-CoA is carboxylated to malonyl-CoA,
which in turn serves as the precursor for the fatty acid chains used to produce hexanoate
(Figure 3) [254,255,261]. The acyl-activating enzyme (AAE), which in Cannabis is encoded
by two putative genes, termed CsAAE1 and CsAAE3, with the encoded proteins localised to
the cytoplasm and peroxisome, respectively, where they function to catalyse the synthesis of
hexanoyl-CoA from hexanoate [255]. Condensation of hexanoyl-CoA, together with three
malonyl-CoA molecules, is subsequently catalysed by the polyketide synthases, tetrake-
tide synthase (TKS), or olivetol synthase [284,285]. The product of these two synthases,
and post a final round of aldol cyclisation by the olivetolic acid cyclase (OAC) enzyme,
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is olivetolic acid (OA) [284]. Via the utilisation of GPP from the MVA pathway, OA is
then prenylated by geranylpyrophosphate:olivetolate geranyltransferase (GOT), to pro-
duce CBGA [286–288]. The cis isomer of GPP, neryl diphosphate (NPP), can be used as a
substrate by GOT in place of GPP, to produce cannabinolic acid (CBNA) [289]. CBGA then
serves as the primary cannabinoid precursor for the synthesis of cannabichromenic acid
(CBCA), THCA and CBDA, with the production of each of these three acids catalysed by a
specific oxidocyclisation enzyme, namely the CBCA, THCA and CBDA synthases [289–293].
The use of divarinic acid as a substitute for OA by GOT, putatively produces the propyl
cannabinoid homolog, cannabigerovarinic acid (CBGVA) [286,294]. The aforementioned
cannabinoid-specific synthases that yield CBCA, CBDA, and THCA can all recruit CBGVA
to produce cannabidivarinic acid (CBDVA), cannabichromevarinic acid (CBCVA) and
∆9-tetrahydrocannabivarinic acid (THCVA), respectively [294–296]. The resulting cannabi-
noids are maintained in their acidic forms until they are thermally decarboxylated to
convert them into their neutral forms [297–300].
Figure 3. An overview of the cannabinoid biosynthesis pathway in Cannabis sativa. Malonyl-CoA,
formed from acetyl-CoA, is used downstream with hexanoyl-CoA to produce olivetolic acid (OA).
Next, OA is used as substrate along with other biomolecules by the GOT enzyme to produce the
major cannabinoid precursor, CBGA. When GOT uses substrates additional to OA, such as divarinic
acid or nerylpyrophosphate, a range of other minor cannabinoids are produced.
Research to date has primarily focused on the biosynthetic pathways and putative
medical benefits of the two major cannabinoids, THC and CBD. Therefore, the medical
and biological potential of the minor cannabinoids that also contribute to the total cannabi-
noid profile of the Cannabis plant have been largely overlooked. The small proportion
that these minor cannabinoids contribute to the total cannabinoid profile of the Cannabis
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plant presents a significant obstacle for in-depth analysis of their effects when consumed.
A comprehensive, and ever-increasing list of naturally occurring minor phytocannabinoids
has been compiled based upon their derivation from THC, CBD, CBG (cannabigerol) and
CBC, which represent the diversity that stems from variations to the three fundamental
components of cannabinoids, including the (1) resorcinyl core; (2) isoprenyl residue, and;
(3) resorcinyl side chain [20,301]. Eighty-two individual cannabinoids from 10 cannabinoid
types, specifically the (1) CBG; (2) CBC; (3) CBD; (4) ∆9-THC; (5) ∆8-THC; (6) cannabicyclol
(CBL); (7) cannabielsoin (CBE); (8) cannabinol (CBN); (9) cannabinodol (CBND), and; (10)
cannabitriol (CBT) types, in addition to the miscellaneous types, and their transforma-
tion products, as well as terpenoids, hydrocarbons, sugars and fatty acids are among
the constituents that comprise the chemical cornucopia of glandular trichomes. Further,
several minor oxygenated cannabinoids, cannabinoid metabolites, and cannabinoid esters
present in Cannabis have yet to be isolated and/or experimentally validated but have been
identified using a variety of spectroscopic techniques [302–304]. In addition, a number of
interesting structural formations have been observed in some of the minor cannabinoids.
For example, cannabioxepane (CBX) has a tetracyclic skeleton with a seven-membered
ring, a structure not previously reported for a characterised cannabinoid, while cannabisol
is a ∆9-THC dimer with a methylene bridge. However, it must be noted that the bind-
ing affinity for specific CB receptors for these minor cannabinoids remains unknown,
with some potentially not recognised, and therefore not bound by any known CB recep-
tor [305,306]. The CBD derivative, cannabimovone, and the farnesyl prenylogue of CBG,
sesquicannabigerol, were also spectroscopically characterised, with CB receptor binding
assays predicting receptor–cannabinoid affinity, highlighting the structural and poten-
tial psychoactive diversity among the minor phytocannabinoids [307,308]. In addition to
the identification of their parent cannabinoid precursors, plausible biochemistry behind
the synthesis of these compounds is offered. However, the actual enzymatic production
of many of these minor cannabinoids remains to be determined. Furthermore, the non-
enzymatic formation of some of the minor cannabinoids is certainly likely, but it remains
of interest to understand whether there is a greater portion of enzyme-catalysed reactions
in the production of the minor cannabinoids, or indeed whether there are alternative
pathways, or even additional pathway entry points in the biosynthesis of cannabinoids,
both minor and primary.
4. Minor Cannabinoids and Their Biological Interactions
There is mounting evidence that the minor cannabinoids described above share com-
binations of many of the same molecular targets as THC and CBD, and therefore may
potentially have unique medical applications that cannot be achieved by THC or CBD
alone. The THC propyl homologue, THCV, is a CB1 and CB2 competitive antagonist
against CP55,940 and WIN55,21–2, acting with similar potency to that of THC [309,310].
THCV also antagonised anandamide and methanandamide in mice vas deferens, atten-
uating stimulated contractile responses [309]. More recently, THCV was shown to sim-
ilarly displace CP55,940 from CB1 and CB2 in CHO cells, and contrary to previous as-
sumptions, was shown to be a weak partial CB1 agonist at high doses [179]. Moreover,
Zagzoog et al. [310] showed THCV to produce anxiolytic, hypothermic, anti-nociceptive,
hypolocomotive, and cataleptic effects in vivo in mice. CB2 agonism by THCV was demon-
strated to reduce inflammation and attenuate hyperalgesia in mice following injection of
carrageenan and formalin, respectively [180]. Neuroprotective properties were observed
in 6-hydroxydopamine lesioned rats, where THCV administration preceded maintenance
of tyrosine hydroxylase-positive neurons in this Parkinsonian model [311]. Similarly,
THCV delayed onset of abnormal involuntary movements associated with Parkinson’s
disease in mice, and reduced their severity after administration following symptom on-
set [181]. The in vitro demonstrated inhibition of GABA release by WIN55,21-2 at Purkinje
cell synapses was reversed by THCV, which also prevented the action of WIN55,212–2
when used in pre-incubation [312,313]. In vitro studies of insulin-resistant human hepa-
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tocytes showed THCV restoration of insulin signaling mediated by CB1, while also im-
proving glucose tolerance and increased sensitivity to insulin in mice obesity models [182].
Antiepileptic properties were also established in vitro, specifically when THCV reduced
both the frequency and amplitude of epileptiform activity in rat piriform cortex slices [183].
The majority of published studies have focused on the CB1 and CB2 receptors, but the
in vitro activity of THCV has been observed for the TRPV1 to TRPV4 group of receptors, as
well as for the TRPA1 receptor [200–202]. THCV can enhance 5-HT1A receptor activation to
produce antipsychotic-like effects in rats [314], but does not affect other endocannabinoid
system constituents such as PPARγ [315], FAAH [200], or MAGL [200]. One clinical trial in
humans where THCV was administered once daily for five days followed by intravenous
administration of THC suggested that THCV inhibited an increase in heart rate, protected
against verbal recall impairment, and reduced the subjective psychoactive intensity in-
duced by THC [316]. Further, THCV affects brain regions associated with reward and
aversive stimuli, as well as areas associated with cognitive control [317,318]
Recently, a four-carbon side chain variant, ∆9-tetrahydrocannabutol (THCB), was iso-
lated and which showed CB1 and CB2 binding affinities similar to those of THC, with
in vivo mice studies suggesting potential analgesic and anti-inflammatory properties [176].
Similarly, the recently identified seven-carbon side chain variant, THCP, was shown to
be able to bind to both CB1 and CB2 with 33 and 5 times greater affinity than THC, re-
spectively, as well as to initiate catalepsy, hypothermia, analgesia, and reduce locomotion;
all indications of potent full CB1 agonism [22]. THCA has been shown in rodent culture
supernatants to reduce the abundance of inflammatory and oxidant markers [319,320],
though no other research to our knowledge of this nature has been published. In addition,
∆8-THC has been shown to possess higher antiemetic effects than THC [188], and has
been successfully trialed for repressing emesis in children [184]. Furthermore, in humans,
∆8-THC appears required to be administered at higher doses than THC to display a sim-
ilar degree of psychoactive properties [321]. THCA is a 5-HT1A agonist [322], a PPARγ
agonist [323], and displays the same properties against TRP channels as does THC [200].
However, little pharmacological, pharmacokinetic, or recent safety data are available for
any of these compounds.
Improvements in seizure frequency has been reported in an epileptic patient coincid-
ing with increased CBDV serum levels, after which in vitro studies confirmed that CBDV,
at least, possesses the ability to influence GABA receptors; a finding that indicates a poten-
tial avenue for anticonvulsant properties [324]. Further, in vitro analyses revealed CBDV to
have anticonvulsant effects in four seizure models, namely the (1) maximal electroshock-,
(2) audiogenic-, (3) penytylenetetrazole-(PTZ), and (4) pilocarpine-induced seizure mod-
els [325,326]. Using rat brain tissue samples, PTZ-induced seizures coincided with an
increase in Early growth response 1 (Egr1), Activity-regulated cytoskeleton-associated protein
(Arc), Chemokine (C-C motif ) ligand 4 (Ccl4), Brain-derived neurotrophic factor (Bdnf ), and FBJ
osteosarcoma oncogene (Fos) gene expression [327]. Interestingly, the administration of CBDV
was shown to reduce the expression of all of these genes [327]. Additional seizure studies
identified TRPV1 as the potential receptor modulating anti-seizure effects via the use of
trpv1 knockout mice which showed a reduced response to CBDV [328]. Desensitisation of
TRPV1, in addition to TRPV2, by both CBDV and CBD has been observed [199], while Ca2+
transients were induced in TRVP2-expressing HEK293 cells more potently by CBD than by
CBDV. However, THC was a more potent inducer of Ca2+ transients than either CBDV or
CBD [200]. Another study did alternately suggest that CBD was the more potent agonist of
TRPV2 than THC, but this study did not include the assessment of CBDV [329]. Cannabi-
noid administration improved symptoms in mice models of Rett syndrome, including
motor control and sociability [197], and through TRPA1, CBDV mediates anti-inflammatory
effects in intestinal tissue of humans with ulcerative colitis [204]. Similar to CBD, CBDV in-
hibits FAAH and anandamide reuptake [200]. However, unlike CBD, CBDV does not show
affinity for the CB1 or CB2 receptors [180]. CBDV may confer some benefit in patients with
Autism Spectrum Disorder [330] and Duchenne muscular dystrophy [205]. CBDV did,
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however, fail to alleviate the neuropathic pain associated with human immunodeficiency
virus (HIV) [331], and in another study, the administration of CBDV induced DNA damage
in human cell lines at concentrations similar to those observed in Cannabis consumers [332],
indicating carcinogenicity potential for CBDV. However, CBDV has been safely trialed in
humans at a single 600 mg oral dose [330], and it remains to be determined whether CBDV
will be efficacious for other illnesses in clinical trial.
CBG has shown partial agonism of CB1 and CB2, α2-adrenceptor agonism and 5-
HT1A antagonism, while exerting some minor anti-nociceptive and anxiolytic properties
in vivo [179,333]. Mice models of inflammatory bowel disease (IBD) showed positive out-
comes with CBG treatment including reductions in the level of reactive oxygen species in
intestinal cells, as well as reduced nitric oxide concentration in macrophages through CB2
modulation [194]. Further in vivo animal studies provided evidence for neuroprotectivity
against symptoms of Huntington’s disease in 3-nitropropionate treated mice, with improve-
ment in motor function, reduction in proinflammatory marker upregulation and increased
antioxidant defenses, with R6/2 mice showing a reduction in the expression profiles of sev-
eral genes linked to the disease following CBG treatment [334]. Similarly, in vitro analysis
of NSC-34 neuronal cells showed that CBG pre-treatment reduced both inflammation and
the expression of pro-inflammatory cytokines, and inhibited cell death resulting from the
cell culture medium of lipopolysaccharide (LPS) stimulated RAW 264.7 macrophages [335].
CBG shows a similar profile at TRP channels compared to CBD, with agonist properties
at TRPV1 through to TRPV4, and at TRPA1, but antagonism at TRPM8 [200]. It is also an
anandamide reuptake inhibitor [336], and an LPI inhibitor at GRP55 [97]. As for the propyl
analogue of CBG, CBGV, very little information surrounding its clinical application exists,
except to show that CBGV has activity at GPR55, TRPV3 and TRPV4 [198,201].
CBC use in a clinical setting, or in human trials, appears to be untested currently,
and additionally, cannabichromevarin (CBCV) currently has even fewer studies dedicated
to it. However, CBC has seen some use in animal models and in vitro studies. CBC has
been shown to inhibit FAAH, MAGL, and anandamide reuptake [200,337], but has been
demonstrated to have no effect at TRPV1 or TRPV2. Further, CBC is a very weak CB1
agonist [338–340], and only exhibits modest agonist properties at CB2. An early study
suggested that CBC, CBCV, and a CBC variant which lacks a carbon side chain, pos-
sessed anti-inflammatory properties in rat edema models and varying anti-bacterial and
anti-fungal properties [341]. More recently, CBC was seen to produce anti-inflammatory
effects in LPS paw edema models in mice in CB1- and CB2-independent pathways and also
produce hypothermia, catalepsy, and locomotor suppression [342]. The authors went on to
suggest that the effects of CBC were altered in the presence of THC, with an additive effect
against inflammation [342] and similarly, tail-flick tests revealed that subtle analgesic prop-
erties of CBC were potentiated by its combination with THC [343]. Selective CB2, but not
CB1 agonism, was exhibited by CBC on mouse pituitary tumour cells, and the persistent
administration of CBC caused desensitisation of CB2 receptors [344]. Intestinal studies
suggest that CBC confers some benefit against inflammation. However, this was potentially
independent of CB1, CB2, or TRPA1, the expression of which were all downregulated in the
presence of CBC in one study, but shown to be unchanged in another study [193,345]. Col-
orectal cancer cell viability was attenuated through TRPM8 antagonism by CBG, as well as
by the administration of CBD, CBDV, and CBC, albeit to lesser degrees [203]. Other studies
have indicated that CBC is not a potent antagonist of TRPM8, and instead suggest that CBD,
CBG, THC, and THCA are more effective antagonists of TRPM8 [200,202]. Additionally,
CBC, CBN, THC, THCV, THCA, CBDA, and CBG all induced intracellular Ca2+ increases
in HEK293 and rat DRG neurons through TRPA1 [200,202]. CBC has also shown promise
in increasing neural stem cell viability in animal models (in vitro), mediated through ERK
phosphorylation [346]. However, it is concerning that large amounts of CBC are required to
produce pharmacological effects [90], which implies that CBC may be difficult to implement
in a human health context.
Biomedicines 2021, 9, 234 16 of 42
The binding affinity of CBN, and of its primary derivatives, to the two main cannabi-
noid receptors was established in 2000, and showed rather unsurprisingly that alterations at
carbon atom positions 1, 3, and 9, resulted in significantly different affinities at both recep-
tors [347]. An earlier study indicated CBN to have cataleptic, hypothermic, and locomotive
effects, as did 11-hydroxy-CBN; a hepatic microsome CYP2C- and CYP3A4-catalysed
metabolite [348,349]. Additionally, CBN directly inhibited the activity of the human cy-
tochrome P450 family 1 (CYP1) enzymes, CYP1A2 and CYP1B1 [350]. Assays of cultured
neuronal cells expressing an inducible disease conferring huntingtin (Htt) protein, sug-
gest that CBN has protective effects against cell death in vivo, with low toxicity even at
the high concentrations required for protectivity [351]. Interestingly, cannabinoid receptor
loss has been indicated as a pathophysiology of Huntington’s disease [352,353], which may
suggest that the purported protective action of cannabinoids is independent of cannabinoid
receptor binding. Subcutaneously delivered CBN delayed the onset of amyotrophic lateral
sclerosis (ALS) symptoms in murine models but failed to affect survival, so was postu-
lated to mask the early spasticity associations without affecting disease progression [354].
A synergistic effect of CBN with CBD at reducing mechanical sensitisation in rat masseter
muscles was observed in one study, however high concentrations of CBD ameliorated the
efficacy of CBN [355]. CBN has been reported to have no effect at FAAH, MAGL, or TRPV1,
but acts as an agonist at TRPA1 and TRPV2 [200].
Via the use of in silico analyses, the even lesser-known cannabinoids, cannabiripsol
(CBR) and CBT, are predicted to have cytochrome P450 inhibitor activity [356]. In another
in silico study, CBL, CBT, and CBE were assessed, and ranked in this order, to have
acetylcholinesterase-inhibiting function. However, their inhibitory effects were less than
those of THC, CBN, and CBDV [357]. Exactly how well in silico studies translate to
clinical relevance, or even to in vitro and/or in vivo studies, restricts what conclusions
can be accurately drawn. Minor phytocannabinoids do represent an understudied portion
of the Cannabis plant. Very few studies exist that have utilised an in vivo approach to
ascertain the viability of minor cannabinoids to potentially produce any significant medical
benefits, and fewer still cover any human clinical trials. There has been indication that some
cannabinoids exhibit synergistic action, and as a result there may be value in investigating
the interactions among cannabinoids or constituents of the Cannabis plant.
5. Directions in Cannabis Development for Secondary Metabolite Production
The establishment of superior varieties of Cannabis has been the target for plant breed-
ers since the domestication of this species. To produce new medically relevant Cannabis
varieties with elevated concentrations of specific minor cannabinoids, or to develop tech-
niques to manipulate the cannabinoid biosynthetic pathway in other organisms, a deeper
understanding of the genetics of the Cannabis plant is first required. Here we outline the
progress in relation to (1) the sequencing of the Cannabis genome, and (2) the potential
to molecularly manipulate the Cannabis plant itself for the altered production of specific
cannabinoids. In this regard, we highlight the established success in Papaver somniferum
(opium poppy), as a parallel example for maximising yield and the concentration of key
secondary metabolites of medical and commercial relevance.
5.1. Next-Generation Sequencing of the Cannabis Plant and Its Potential for Genetic Manipulation
Over the last 25 years, various experimental approaches have been employed to unveil
the wealth of information contained in the Cannabis genome. Using early DNA sequencing
and karyotyping techniques, the X and Y sex chromosome characteristics of Cannabis were
uncovered, as were the diploid (2n = 20) genome sizes for male and female plants [358,359].
The female Cannabis plant was revealed to have a genome size of 818 megabase (Mb),
while the male Cannabis plant was determined to have a larger genome size of 843 Mb;
specifically due to the larger size of the Y chromosome, compared to the X chromosome of
female plants [358]. Microsatellite markers have been employed as a tool for DNA typing
Cannabis, and these polymorphic short tandem repeat (STR) markers have been utilised as
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a measurement of genetic relationships among cultivars [360–362]. More recently, the rapid
change in technologies surrounding Next-Generation Sequencing (NGS) platforms has
meant that studies can unravel whole genomes in a fraction of the time required via the use
of older methods. As a result, the first draft Cannabis reference genome, and transcriptome,
were constructed in 2011 using the high THCA, low CBDA cultivar, ‘Purple Kush’, and the
high CBDA, low THCA hemp strains, ‘Finola’ and ‘USO-31’ [363]. Using a PacBio long-read
sequencing platform, the Purple Kush and Finola genomes were again sequenced in 2019
to generate a physical and genetic map for Cannabis, and further distinguish the genes,
and importantly the gene products (specifically, the encoded enzymes), underpinning the
secondary metabolite profiles responsible for the divergent chemotype between hemp and
marijuana cultivars [364,365].
Earlier work surrounding the chemotypic variance of cannabinoids observed in
Cannabis unveiled the relationship between THCA and CBDA synthase expression, describ-
ing a single locus (B), with two codominant alleles, BD and BT [295]. A 1:1:2 segregation
ratio results in the production of three chemotypes of the B locus, including the (1) pure
CBD (BD/BD homozygote), (2) pure THC (BT/BT homozygote), and (3) mixed CBD/THC
(BD/BT heterozygote) chemotypes [295]. However, later studies based around NGS plat-
forms indicated an alternate genetic model of synthase gene duplication and rearrangement
at multiple linked loci, and that CBDA synthase is more ancient, has a greater affinity
for the CBGA substrate, and that the CBDA synthase locus is solely responsible for the
cannabinoid chemotypes observed in Cannabis [363,365–369]. In an attempt to classify
variability in chemotypes, and to associate genotype to chemotype in a diverse germplasm
collection, DNA sequence characterised amplified region (SCAR) markers associated with
THCA/CBDA synthases were assessed in 22 Cannabis varieties representing 2 fibre and 1
drug type plants from East (n = 8), Central (n = 1), and South (n = 2) Asia, as well as from
Europe (n = 7) and of mixed (n = 4) domestication status [370]. This approach revealed a
variability in cannabinoid profiles (CBD:THC) across ‘chemotype II’, or BD/BT equivalent
plants, more than three-fold greater than previously observed, supporting the allelic variant
and multiple loci prediction, when assuming that a heterozygote plant in a single locus
model would have a 1:1 CBD:THC ratio [370].
Other large-scale genetic diversity studies using NGS, and which compared the evo-
lutionary relationships between 340 Cannabis varieties from existing datasets, and from
other novel multiplexed libraries, highlighted the murky ancestry of the Cannabis plant
resulting from generations of repeated rounds of selective breeding, and also provides an
extensive data platform for future genotyping efforts [371]. Moreover, Lynch et al. [371]
classed their assessed Cannabis varieties into three genetic groups, including (1) hemp, (2)
narrow leaflet, and (3) broad leaflet drug types, in order to determine the genomic and
genetic variation of their population for the potential use of varieties from each group in
either agricultural or medicinal applications. The authors indicated unique cannabinoid
and terpenoid profiles for each group, structured loosely around geographic origin of each
species, and noted the requirement for the inclusion of the putative Cannabis species, C. rud-
eralis, in future studies to fully elucidate their genetic distinction and ancestral lineage [371].
The development of expressed sequence tag simple sequence repeat (EST-SSR) markers
to assess genetic diversity of 115 Cannabis genotypes also revealed geographical-based
clustering into 4 groupings, including the Northern China, Southern China, Central China
and Europe groupings [372]. Interestingly, a genetic similarity coefficient derived from
45 of 117 randomly selected EST-SSRs markers revealed that despite physical proximity
to the other Chinese varieties, Northern Chinese varieties had a greater similarity coeffi-
cient to the European grouping, predicted to be related to latitude and day length [372].
The analysis of inter simple sequence repeats (ISSR) of 27 native Chinese hemp varieties
identified a similar geographic distribution to genetic distance relationship, while also
revealing the hemp varieties were genetically diverse, yet primitive, a finding which adds
further weight to the suggestion that the Cannabis plant originated in southern China and
then spread north [373].
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The recent assembly and annotation of the mitochondrial genome of Cannabis using
NGS methods will also allow for similar studies to be performed to determine the extent
of the genetic diversity among Cannabis varieties [374]. In addition, the assembly of two
chloroplast genomes from different Cannabis varieties will aid in validating the phylogenetic
relationship of Cannabis among the Rosales order of the Plantae kingdom [375]. However,
as with all sequencing, repeated efforts across diverse genotypic populations compared
against reference genomes will increase the accuracy and reliability of publicly available
repositories. RNA sequencing as a tool for differentiating strains has been used with
some success, where the transcriptome isolated from cannabinoid-containing glandular
trichomes from different varieties allows for comparative analysis based on the cannabinoid
and terpenoid chemical profiles [376,377]. As the regulatory landscape surrounding the
use of Cannabis evolves, and the value of the unique chemical profile of specific Cannabis
varieties is realised, breeders are likely to use these sequencing techniques to rapidly
characterise and protect their ‘strains’. The development of such highly targeted databases
provides the platform for precise manipulation of phenotypic or chemotypic traits in
Cannabis to deliver improved medical efficacy or novel therapeutics.
A forward and/or reverse genetics approach with the application of chemical muta-
genesis agents, such as ethyl methanesulfonate (EMS), a mutagen that introduces point
mutations into the plant genome, is an effective approach for functional genomic assess-
ments and effective plant breeding regimes, and has been successfully demonstrated in a
variety of plant species, including hemp [9,378–383]. The application of alkylating agents
such as EMS in a time-dependent manner causes a larger number of point mutations
across the genome, compared to an irradiating method such as X-ray, or fast neutron
bombardment, both of which produce much larger genome deletions and/or chromosome
rearrangements [384–386]. Deletions ranging from 0.8 to 12 kilobases (kb) were produced
in Arabidopsis using fast neutron bombardment, a widely used model plant species with an
average gene density of one gene per 4.8 kb. The size of the genome alterations produced
by this approach can, however, potentially cause the loss of function, or significantly altered
expression of more than one gene. Therefore, a considerable drawback of using such an
approach is the time and effort required post-mutagenesis to identify a ‘causative mutation’.
While the Arabidopsis genome is comparatively smaller than that of Cannabis, a similar
post-mutagenesis investigative strategy would likely be required in other plant species
with nuclear genomes either of a similar or significantly larger-size [385,387]. Regardless,
these types of methods require rather large numbers of plants to be effective as deletions
and point mutations are not site directed, which is a considerable limitation as even rapid
standard screening techniques demand intensive laboratory work [388–390].
Since the advent of the CRISPR/Cas9 gene-editing system in late 2012 [391], the abil-
ity to manipulate plant genomes has become more cost efficient and less experimen-
tally tedious when compared to the traditional genetic engineering approaches used by
plant breeders in other crop species [392]. The CRISPR/Cas9 system effectively directs
site-specific genome editing using RNA-guided, microbial-derived nucleases that initiate
double-stranded DNA breaks in eukaryotic and bacterial systems [391,393]. The speci-
ficity of this system greatly reduces the amount of off-target genome alterations compared
to more traditional transformation techniques. However, off-targeting has also been ob-
served with CRISPR/Cas9 use, an inherent challenge when manipulating any biological
system [394–397]. Earlier work was directed towards human applications, but increas-
ingly this system has been utilised in plant systems, with examples in Arabidopsis, tobacco
(Nicotiana tabacum), rice (Oryza sativa), lettuce (Lactuca sativa), maize (Zea mays), soybean
(Glycine max) and wheat (Triticum aestivum) now documented [398–410]. By no means
an exhaustive list of CRISPR/Cas9-facilitated manipulation in plants, the above does,
however, highlight the potential applicability of this targeted mutagenesis approach to
modulate specific biosynthetic pathways in Cannabis to produce superior varieties that
display phenotypic and chemotypic traits of interest, and as a tool to discover key genes
involved the production of minor cannabinoids. Transformation technologies has thus far
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been conducted in hemp varieties only, and therefore require further development and con-
siderable refinement for application in other Cannabis varieties. The first report of successful
hemp transformation emerged in 2001 [411], and two years later, a protocol for successful
Agrobacterium tumefaciens-mediated transformation of tissue cultured hemp callus was
implemented [412]. More recently, Wahby et al. [413,414] successfully transformed hemp
using both A. tumefaciens and A. rhizogenes, establishing the initial protocol for hairy root
culture in Cannabis, a system used for the production of key phytochemicals. Despite these
successes, Cannabis has proven to be a difficult plant species to transform with such vari-
ables as variety, plant age and the explant used for callus production, all demonstrated to
be crucial factors underpinning transformant regeneration efficiency [415]. As with any
novel plant transformation system, in order to overcome poor transformation efficiency,
optimised protocols with respect to culture media, experimental approach, and selected
explant material, will be required for routine and robust transformation of Cannabis.
5.2. Synthetic Production of Cannabinoids
Recently, the synthetic biology approach utilising microorganisms to produce high-
quality cannabinoid products has removed the requirement for plant material [287,416].
Luo and colleagues [287] were successful in producing CBG, CBD, THC and ∆9-THCV from
galactose, via manipulation of the native MVA pathway of the yeast Saccharomyces cerevisiae
post the introduction of Cannabis genes encoding cannabinoid synthases, olivetolic acid
synthase and geranylpyrophosphate: olivetolate geranyltransferase. Production of THCA
from CBGA through functional THCA synthase expression in the two yeast species, S.
cerevisiae and Pichia pastoris, has been demonstrated. However, attempts to introduce the
same functionality in Escherichia coli, a bacterium, have proved unsuccessful [293,417].
Over-expression of genes encoding enzymes in the MVA and prenyl diphosphate path-
ways, also in S. cerevisiae, produced prenyl alcohol precursors required for terpenoid and
cannabinoid synthesis [418], while expression of a functional aromatic prenyltransferase
from Streptomyces resulted in THCA production from OA and DPP in the yeast, Koma-
gataella phaffi [419]. These approaches present an attractive alternative with the ability
to conceivably produce large quantities of minor cannabinoids that are only found in
trace amounts in planta, while also reducing and/or removing the costs, carbon emissions
(associated with indoor growth; [420]) and environmental variables associated with the
agricultural crop production. However, it should be noted that due to the criminalisation
of Cannabis since the early 1930s, there are very few studies analysing water and energy
use associated with the cultivation of Cannabis, although undoubtedly, as research in this
area becomes more prevalent, efficient horticultural practices will reduce the consumption
of water and energy for the large-scale cultivation of Cannabis.
5.3. Phenotypic Parameters Affecting Cannabis Yield and Potency
In Cannabis plants exhibiting an illicit drug chemotype (high THC), a primary con-
cern, in conjunction with desired cannabinoid content, is overall biomass yield of female
floral tissue. Consistent with other agriculturally significant species, Cannabis is sensi-
tive to environmental variations which alter physiological characteristics affecting plant
growth and yield potential. Early work on Cannabis flowering, uncovered the response to
photoperiodism [421,422], which has subsequently been exploited, particularly by illicit
indoor growers, who can cultivate Cannabis year-round by manipulating the response to
reduced photoperiod length [423]. Photoperiodism is a well-known biological response
critical for development of branching and floral architecture in Cannabis, and as a result,
has implications for yield potential [423,424]. A reduction in day length from 18 to 12 h
induces flowering, and maintenance of this regime for 8 weeks produces an acceptable
floral yield [423]. Elevated light intensity from 400 watts per square metre (W m−2),
to 600 W m−2, produced a higher yield of floral tissue per plant in several chemotypes
when grown indoors [424]. In addition, an increase in plant density from 16 to 20 plants m−2
reduced biomass yield of floral tissue in all 600 W m−2 treated plants [425]; a finding that
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indicates that light interception is compromised at the lower canopy level in crowded
growth conditions. The use of different artificial lighting systems in controlled environ-
ment greenhouse applications also affects yield, but there are ‘trade offs’ when using light
emitting diode (LED), versus high-intensity discharge (HID) light sources. HID lighting is
generally of lower cost and generates greater photon flux density between 400 and 700 nm,
while LED lighting has greater configurability for specified needs and emits substantially
less heat than HID lighting; with both lighting options having similar electricity to photo-
synthetic photon conversion efficiencies, expressed as, µmol J−1 [426–428]. The importance
of light quality has been demonstrated in cucumber (Cucumis sativus) where a significant
increase in dry weight was measured in plants grown under an ‘artificial solar spectrum’,
produced by sulfur plasma and quartz-halogen lamps irradiating a light spectrum that
emulated standard sunlight, when compared with those plants provided with either flu-
orescent or HID lighting [429]. Photosynthetic photon flux density significantly affects
harvestable floral biomass yield, while elevated UV-B radiation and electrical lighting
power density (W m−2) increased the ‘potency’ of Cannabis through an elevation in THC
concentration; all of which highlight the importance of light quantity and quality capture by
the photosynthetic apparatus of this species to improve the harvestable output of cultivated
Cannabis [423,430–433].
Manipulating temperature conditions in indoor growth facilities has revealed a re-
lationship with factors affecting plant growth and development. Rate of photosynthesis,
water use efficiency, rate of transpiration, and leaf stomatal conductance, all increased
in Cannabis plants with a temperature increase from 20 to 30 ◦C, suggesting an optimal
temperature range for cultivation [431]. Temperature and photosynthetic rate are tightly
linked with the photosynthetic apparatus sensitive to fluctuations in temperature, re-
sponding particularly with reduced Ribulose 1,5-bisphosphate (RuBP) regeneration and
lowered stomatal aperture, which together decreased CO2 uptake; both rate reducing
outcomes [434–436]. It is worthwhile to note that Cannabis varieties are similarly sen-
sitive to temperature where photosynthetic rate, water use efficiency, leaf number, and
stem elongation, are modulated in response to temperature change [431,437,438]. Min-
eral supplementation via fertilizer application has produced mixed results in terms of
biomass and secondary metabolite concentration and/or profile composition in Cannabis.
Cannabis was shown to be sensitive to nitrogen (N), phosphorus (P) and potassium (K)
(NPK) supplementation, as well as the plant biostimulant, humic acid. The application
of NPK reduced THC, CBN and CBD content, but increased CBG content in the Cannabis
inflorescence, while the application of humic acid was found to significantly lower the THC,
CBD, CBG, THCV, CBC, CBL and CBT content of the Cannabis inflorescence [439]. However,
N supplementation alone increased hemp seed yield, plant height, chlorophyll content,
while decreasing fibre yield [440]. The application of exogenous hormones during distinct
developmental phases of Cannabis growth has also produced mixed results in relation to
secondary metabolite content and biomass. Gibberellic acid (GA) application to whole
flowering plants with developed, resinous trichomes reduced chlorophyll levels, DXS ac-
tivity, mono- and sesquiterpene levels, and THC content, while increasing HMGR activity,
to suggest a degree of interference (either directly or indirectly) by GA to both the MVA
and MEP pathways [441,442]. Abscisic acid (ABA) application at the vegetative stage of
Cannabis development, increased chlorophyll a content, but reduced HMGR, THC and CBD
content. In contrast, ABA application at the flowering stage of development decreased total
chlorophyll and HMGR content, and increased DXS activity and the content of THC in the
flowers of female Cannabis plants, findings which again indicated either direct or indirect
phytohormone-mediated interference of both the MVA and MEP pathways [441,442].
Alterations of the architecture of the Cannabis flower via the application of molecular-
assisted breeding, or genetic engineering, are potential strategies to increase the floral
yield of Cannabis. Alternatively, directed manipulation of the biosynthetic pathways by
application of similar approaches leading to increased cannabinoid or terpenoid content
would provide greater value via the targeted elevation of the exact concentration of spe-
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cific secondary metabolites. Currently, research describing the implementation of such
strategies in Cannabis are scarce. However, investigations of trichome development in
Arabidopsis and other plant species are not. The extremely well-annotated genome of
Arabidopsis, combined with the ease that Arabidopsis can be genetically manipulated, identi-
fies Arabidopsis for use in baseline studies that are potentially applicable to more valuable
agricultural species. Indeed, Arabidopsis-based studies of trichome development have
revealed a cohort of genes of interest. As with the development of any specialised cell type,
it is underpinned by a complex gene network, and in Arabidopsis, the protein products
encoded by the GLABROUS1 (GL1), GL2, GL3 and TRANSPARENT TESTA GLABROUS
loci are responsible for various aspects of trichome morphogenesis, maturation, branching
and spatial variation [443–446]. Additional gene products have been identified as essential
for correct branching patterns and trichome responses to hormones, with EMS-induced
mutation to the MYB encoding gene, TRIPTYCHON, resulting in the ‘nesting’, or grouping
of trichomes with higher local densities [447,448]. A gene encoding a zinc-finger transcrip-
tion factor from Arabidopsis, GLABROUS INFLORESCENCE STEMS, increased glandular
trichome density on the leaves, sepals, inflorescence and its branches, while also increas-
ing the content of nicotine secretion into the glandular heads when over-expressed in
tobacco plants [449]. Similarly, overexpression of a serine proteinase inhibitor, SaPIN2a,
from American nightshade (Solanum americanum) in transformed tobacco, significantly
increased the branching and density of glandular trichomes [450]. Regulation of the ex-
pression of the gene encoding the DXS synthase 2 (DXS2) enzyme, which is active in the
MEP pathway in Cannabis, and also in tomato (Solanum lycopersicum) via a RNA silenc-
ing approach, resulted in an increase in trichome density on tomato leaves and reduced
the accumulation of the monoterpene, β-phellandrene [451]. In cotton (Gossypium spp.),
a mutation in the PIGMENT GLAND FORMATION locus, resulted in the expression of the
glandless phenotype: a strategy adopted to remove toxic gossypol from cotton seeds for
human consumption [452]. While the opposite phenotypic outcome of increased trichome
density would be the desired result in Cannabis experimentation, when taken together,
these findings highlight the importance of targeting specific genetic networks for molecular
manipulation to initiate the expression of desired and/or designer plant phenotypes.
Increasing the biomass of agriculturally valuable species is not a novel undertaking,
and anthropogenic selection has perhaps inadvertently, been conducted by humans since
the dawn of agriculture. Plant height is identified as a target for manipulation in relation to
overall biomass yield in maize and sorghum (Sorghum bicolor) [453], and in Cannabis grown
for fibre, stem length is an important parameter for fibre yield which is affected by plant
density and soil N content [454,455]. The inverse is true for Cannabis varieties grown for
their cannabinoid content, where reduced stem lengths produce a shorter overall plant
stature and correlates with a greater photoassimilate input into reproductive tissues leading
to the development of floral architecture with increased accumulation of cannabinoids
and terpenoids [456]. Small [3] suggests that the value of drug chemotype varieties is
linked to the development of ‘semi-dwarf Cannabis germplasm’, characterised by compact,
congested flowers on short branches. Such plants ultimately produce more cannabinoids
due to greater resource partitioning into floral and trichome development and are of
short enough stature that they can be grown at high indoor densities where the artificial
environment is readily manipulated to produce greater amounts of secondary metabolites.
The combination of key phenotypic traits associated with increased secondary metabolite
accumulation, including dense compact floral arrangements, and semi-dwarf stature,
and with novel chemotypic traits that confer targeted medical efficacy epitomises the
new varieties (chemovars) to be pursued as part of a highly focused research strategy.
Similar strategies that use marker assisted breeding and EMS to provide the molecular
basis to generate plants that produce elevated levels of desired compounds have been
undertaken in other medically significant plant species. Quantitative trait loci mapping of
Artemisia annua L. (sweet wormwood), a plant species which produces the anti-malarial
compound, artemisinin, provided the platform for marker assisted breeding programs to
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increase artemisinin yield [457], and by extension, revealed both the pathway for similar
research that would later be undertaken in opium poppy and the avenues for the future
development of similar strategies in Cannabis.
5.4. Papaver somniferum: Potential Parallels for Future Cannabis Research
With significant change surrounding the societal views and scientific inquiry into
Cannabis on the horizon, it is important to look at past endeavours to envisage future
directions. While Cannabis is a unique plant for its utility, Papaver somniferum (Papaver;
opium poppy) rivals the versatility seen across Cannabis varieties, and given its long history
of human use, it is an excellent comparison to investigate. Papaver, otherwise known as
opium poppy, is responsible for the production of the most medically significant alka-
loids, including morphine, codeine, thebaine, oripavine and noscapine. These opioids
accumulate in the phloem, particularly the mesocarp capsule of Papaver aerial tissues in
specialised cells called lactifers, which join to form a latex-containing network of anas-
tomosing vessels [458–460]. The therapeutic efficacy of Papaver-derived opioids is better
understood than the secondary metabolites of Cannabis, and the scope of their effects is
far reaching. Morphine has been utilised for decades as one of the most widely used anal-
gesics, effective in the post-operative clinical setting [461–463]. Codeine has been shown
to be a less effective analgesic than morphine [464,465] but has historically been accepted
as the prevailing antitussive [466]. More recent evidence suggests however, that there
are more effective treatments, especially for chronic coughing disorders [467–469]. Addi-
tionally, noscapine, another Papaver alkaloid, displays antitussive properties, and is also
suggested to potentially mitigate stroke mortality and induce apoptosis in a broad set
of cancers [470–473]. Thebaine and oripavine are not themselves used therapeutically.
However, they are precursors for a wide range of semi-synthetic opioids including, but not
limited to, hydrocodone, oxycodone and hydromorphone, as well as naloxone, which is
interestingly employed to treat the acute effects of opioid overdose [474–479].
Given the multitude of efficacious compounds produced by Papaver, and the com-
mercial value emanating from such, the desire to generate plant varieties that produce
specific chemical profiles is one that is mirrored in Cannabis. While the latter is currently
reliant on years of predominantly illicit breeding programs to produce plants with in-
creased psychoactive properties, the development of novel Papaver varieties has already
been established. EMS treatment of poppy seeds preceded the identification of a variety
termed top1 (thebaine oripavine poppy 1) which harboured a mutation leading to prema-
ture arrest of the morphine and codeine biosynthesis pathway. The resulting top1 plants
displayed a pigmented latex, and the enhanced accumulation of thebaine and oripavine,
but failed to produce either codeine or morphine [480]. Similarly, a reduction in codeine
3-O-demethylase (CODM) activity, via either a viral-induced gene silencing (VIGS) strat-
egy, or a fast neutron bombardment mutagenesis approach, yielded Papaver plants with
enhanced codeine accumulation, but which were unable to synthesise morphine from a
codeine substrate [481–483]. These high codeine Papaver varieties that harbour CODM
polymorphisms, provided a basis for a marker-assisted breeding platform, and to produce
Papaver chemotypes accumulating novel alkaloid profiles [483]. Similar actions utilising
Cannabis may also mediate alterations to the cannabinoid biosynthesis pathways to produce
varieties with elevated minor cannabinoid content. Sequencing of a high noscapine variety
of Papaver, termed HN1, led to the discovery of a 10 gene cluster responsible for noscapine
biosynthesis that was absent in either a high morphine (HM1)- or high thebaine (HT1)-
producing variety of Papaver [484]. Generation of an F2 mapping population from HN1 and
HM1 parents showed tight linkage of this gene cluster, revealing high noscapine-producing
progeny that were homozygous for the HN1 gene cluster, while heterozygosity, or absence
of the HN1 gene cluster, was associated with plant lines that produced low or undetectable
levels of noscapine, respectively [484]. The identification of the STORR ([S]- to [R]-reticuline)
locus led to the development of high noscapine Papaver varieties with a non-functioning
cytochrome P450-oxidoreductase fusion protein, inhibiting the [S]-reticuline conversion
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to [R]-reticuline necessary for completion of the morphinan pathway [485–488]. A VIGS
approach has been successfully utilised to individually regulate the expression of six genes
encoding enzymes involved in the final six conversion steps of [R]-reticuline to morphine,
each of which were shown to alter the major alkaloid profile [489]. An RNA silencing
approach which employed a chimeric hairpin RNA to target all members of the multi-
gene codeinone reductase family produced a non-narcotic, [S]-reticuline-accumulating
variety of Papaver [490]. In the exploitation of the versatility of Papaver beyond narcotics,
varieties with high food value have been established through EMS and gamma ray mu-
tagenesis breeding programs to produce increased seed yield (5.66 g/capsule versus the
3.39 g/capsule of control plants) with elevated levels of unsaturated seed oil and no nar-
cotic production [491]. While this is not an exhaustive list of selectively bred, or engineered
Papaver varieties, the long-standing and successful development of Papaver varieties with
superior phenotypic and/or chemotypic traits of interest certainly provides a reference for
guiding Cannabis research strategies, which at present are comparatively in their infancy.
Development of varieties producing high levels of alkaloid biosynthetic pathway inter-
mediates is a promising indicator for the potential production of Cannabis varieties that
reliably produce high levels of minor cannabinoids or intermediates in the cannabinoid
biosynthesis pathway.
6. Conclusions
In summary, we have reviewed the current literature of several important aspects
of cannabinoid research outside of THC and CBD, which dominate discussion in the
Cannabis research field. Emerging research has begun to reveal the pharmacology and
molecular targets of the minor cannabinoids. Due to the wide spectrum of molecular
effects involved with cannabinoid consumption, it is clear that there are a range of medical
ailments that could be addressed through endocannabinoid augmentation using secondary
metabolites of Cannabis. Here, we have illustrated that via the utilisation of specific minor
cannabinoids, which share some, but not all targets of THC and CBD, the medical reach of
cannabinoid-containing pharmaceuticals could potentially be broadened. However, there
are many challenges that currently impede this possibility, even outside of the international
legal environment. Firstly, there is further room for significant characterisation of minor
cannabinoid pharmacology, and currently, disease-orientated preclinical and clinical trials
are lacking. Critically, techniques for producing cannabinoid isolates—even CBD and
THC—are still in their infancy, and this remains a clear barrier to large-scale commerciali-
sation of pharmaceutical cannabinoids. Here, we have reviewed the currently available
literature which covers the processes involved in the biosynthesis of cannabinoids, as well
as the techniques involved in the production of novel Cannabis chemotypes, including
methods of improving yield that might be adopted from historically similar cases, such
as the opioid industry. Based on this historical example, and the existing literature, it is
likely that a molecular genetic modification approach will be applied to Cannabis to gener-
ate new opportunities for the improved yield of specific minor and major cannabinoids
in the near future. In conclusion, there are multiple enticing and potentially profitable
opportunities for commercial and academic growth in the Cannabis market outside of THC
and CBD, and here, we highlight some of the most important current perspectives of this
growing industry.
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415. Ślusarkiewicz-Jarzina, A.; Ponitka, A.; Kaczmarek, Z. Influence of Cultivar, Explant Source and Plant Growth Regulator on Callus
Induction and Plant Regeneration of Cannabis sativa L. Acta Biol. Cracoviensia Ser. Bot. 2005, 47, 145–151.
416. Carvalho, Â.; Hansen, E.H.; Kayser, O.; Carlsen, S.; Stehle, F. Designing Microorganisms for Heterologous Biosynthesis of
Cannabinoids. FEMS Yeast Res. 2017, 17, Fox037. [CrossRef] [PubMed]
417. Zirpel, B.; Stehle, F.; Kayser, O. Production of ∆9-Tetrahydrocannabinolic Acid from Cannabigerolic Acid by Whole Cells of Pichia
(Komagataella) Pastoris Expressing ∆9-Tetrahydrocannabinolic Acid Synthase from Cannabis sativa L. Biotechnol. Lett. 2015, 37,
1869–1875. [CrossRef] [PubMed]
418. Ohto, C.; Muramatsu, M.; Obata, S.; Sakuradani, E.; Shimizu, S. Overexpression of the Gene Encoding HMG-CoA Reductase in
Saccharomyces Cerevisiae for Production of Prenyl Alcohols. Appl. Microbiol. Biotechnol. 2009, 82, 837–845. [CrossRef] [PubMed]
419. Zirpel, B.; Degenhardt, F.; Martin, C.; Kayser, O.; Stehle, F. Engineering Yeasts as Platform Organisms for Cannabinoid Biosynthesis.
J. Biotechnol. 2017, 259, 204–212. [CrossRef]
420. Mills, E. The Carbon Footprint of Indoor Cannabis Production. Energy Policy 2012, 46, 58–67. [CrossRef]
421. Borthwick, H.A.; Scully, N.J. Photoperiodic Responses of Hemp. Bot. Gaz. 1954, 116, 14–29. [CrossRef]
422. Schaffner, J.H. The Influence of Relative Length of Daylight on the Reversal of Sex in Hemp. Ecology 1923, 4, 323–334. [CrossRef]
423. Potter, D.J.; Duncombe, P. The Effect of Electrical Lighting Power and Irradiance on Indoor-Grown Cannabis Potency and Yield. J.
Forensic Sci. 2012, 57, 618–622. [CrossRef]
424. Spitzer-Rimon, B.; Duchin, S.; Bernstein, N.; Kamenetsky, R. Architecture and Florogenesis in Female Cannabis sativa Plants. Front.
Plant Sci. 2019, 10, 350. [CrossRef]
425. Vanhove, W.; Van Damme, P.; Meert, N. Factors Determining Yield and Quality of Illicit Indoor Cannabis (Cannabis Spp.)
Production. Forensic Sci. Int. 2011, 212, 1. [CrossRef] [PubMed]
426. Viršile, A.; Olle, M.; Duchovskis, P. LED Lighting in Horticulture. In Light Emitting Diodes for Agriculture: Smart Lighting; Springer:
Singapore, 2017; pp. 113–147. [CrossRef]
427. Nelson, J.A.; Bugbee, B. Economic Analysis of Greenhouse Lighting: Light Emitting Diodes vs. High Intensity Discharge Fixtures.
PLoS ONE 2014, 9, e99010. [CrossRef]
428. Tamulaitis, G.; Duchovskis, P.; Bliznikas, Z.; Breive, K.; Ulinskaite, R.; Brazaityte, A.; Novičkovas, A.; Žukauskas, A. High-Power
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